Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

Calabrese, Joseph R.; Guelfi, Julien Daniel; Perdrizet-Chevallier, C.

doi:10.1111/j.1399-5618.2007.00507.x

Cited by 119 publications

(69 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melatoninergic effects have recently emerged as a potential target for bipolar disorder [4] and a component of treatment with the antidepressant agomelatine, a MT1 and MT2 agonist with 5HT-2C antagonist properties [5] . One case series of agomelatine added to mood stabilizers for 21 patients with bipolar depression resulted in 81% responding, with 3 patients becoming manic [6] . Melatonin 3 mg added to mood stabilizers was found effective for resistant insomnia in 11 cases who had mania [7] .…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Nierenberg¹

2009

Psychother Psychosom

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Nierenberg¹

2009

Psychother Psychosom

View full text Add to dashboard Cite

“…36 Its efficacy in depression in bipolar I patients, in combination with either lithium or valproate, has also been assessed in an open-label study ranging from 6-46 weeks. 37 In addition, it has been suggested that agomelatine may show efficacy in the long-term maintenance treatment of alcoholism, to prevent alcohol-related brain damage. 38 Other areas of research include its use as an adjunct in autism and benzodiazepine withdrawal.…”

Section: Other Disordersmentioning

confidence: 99%

Agomelatine: a review for general practitioners

Outhoff

2012

South African Family Practice

View full text Add to dashboard Cite

The 24-hour rhythms of life, including the timing of sleep induction, wakefulness, hormone secretion, thermoregulation, glucose homeostasis and fat metabolism, are governed by external environmental time signals AbstractAgomelatine is a novel melatonergic antidepressant that restores disrupted biological rhythms, essentially by resetting the circadian clock. Two different, non-monoaminergic, and possibly synergistic pathways, appear to be involved in its mechanism of action. Agomelatine is a melatonin 1 (MT 1 ) and melatonin 2 (MT 2 ) receptor agonist and serotonin (5-hydroxytryptamine) 2C (5-HT 2C ) receptor antagonist. It is effective in treating moderate-to-severe depression, alleviating the symptoms of anxiety, and restoring the disrupted sleep patterns that often result from this potentially devastating disease. Agomelatine is generally well tolerated with little, if any, propensity for antidepressant-induced sexual dysfunction, weight gain, or discontinuation reactions. However, it has the potential to cause temporary hepatotoxicity, and liver functions need to be monitored as a result. Clinically, meaningful drug interactions are unlikely, with the exception of co-administered potent cytochrome P 1A2 (CYP1A2) enzyme inhibitors, which may increase agomelatine's plasma levels significantly. Agomelatine represents an interesting addition to the antidepressant market.Peer reviewed.

show abstract

“…In patients with seasonal affective disorder, 25 mg of agomelatine over 14 weeks was associated with significant improvements in the Structured Interview Guide for the HAM-D, with a particular improvement in sleep disturbance and daytime fatigue [Pjrek et al 2007]. Adjunctive use in patients with bipolar type 1 disorder also showed improvement in HAM-D scores [Calabrese et al 2007] and the risk of triggering a manic switch was similar to that seen with venlafaxine [Calabrese et al 2007]. This small study involved 21 patients with type I bipolar disorder who were prescribed concurrent mood-stabilizing agents (either lithium or valporic acid).…”

Section: Introductionmentioning

confidence: 99%

Agomelatine in unipolar depression in clinical practice: a retrospective chart review

Langan¹,

Shajahan²,

Martin³

et al. 2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Agomelatine (Valdoxan), a synthetic melatonergic receptor agonist at the MT 1 and MT 2 receptors, was first used in the management of sleep disorder. Its 5HT2C receptor antagonistic properties support its antidepressant potential. It is currently licensed in the UK, Europe and USA for the treatment of major depressive disorder. Although the randomized controlled evidence base for its use is growing, there are no retrospective, naturalistic studies available. We aimed to determine the tolerability and clinical effectiveness of agomelatine in unipolar depression. We also examined whether being refractory to treatment altered clinical outcome. Forty-eight patient records were examined. Twenty-five percent were treatment refractory: Clinical Global Impression (CGI) Severity score at the start of treatment was 3.81 compared with 3.38 at the end of treatment. Fifty-four percent improved at least minimally; only 12.5% were much or very much improved. Treatment-refractory patients had a poorer outcome with higher discontinuation rates and lower CGI Improvement (p = 0.0205). Treatment-refractory patients also had a higher CGI Severity score at the end of treatment than at treatment commencement (3.92 versus 3.75), although this was not statistically significant.

show abstract

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

Abstract: These results indicate the effectiveness of agomelatine 25 mg in the treatment of depressed bipolar I patients co-medicated with lithium or valpromide. A randomized controlled trial is planned to confirm these results.

Cited by 119 publications

References 28 publications

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Agomelatine: a review for general practitioners

Agomelatine in unipolar depression in clinical practice: a retrospective chart review

Contact Info

Product

Resources

About